UA86731C2 - Делимая галеновая форма модифицированного высвобождения активного ингредиента - Google Patents

Делимая галеновая форма модифицированного высвобождения активного ингредиента

Info

Publication number
UA86731C2
UA86731C2 UAA200810556A UAA200810556A UA86731C2 UA 86731 C2 UA86731 C2 UA 86731C2 UA A200810556 A UAA200810556 A UA A200810556A UA A200810556 A UAA200810556 A UA A200810556A UA 86731 C2 UA86731 C2 UA 86731C2
Authority
UA
Ukraine
Prior art keywords
divisible
drug release
galenic form
modified drug
galenic
Prior art date
Application number
UAA200810556A
Other languages
English (en)
Ukrainian (uk)
Inventor
Жиль Фонкнехтен
Патрик Женти
Жан-Манюель Пен
Патрик Вютриш
Original Assignee
Ле Лаборатуар Сервье
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39796790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA86731(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ле Лаборатуар Сервье filed Critical Ле Лаборатуар Сервье
Publication of UA86731C2 publication Critical patent/UA86731C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Изобретение относится к делимой галеновой форме модифицированного высвобождения активного ингредиента, где неразделенная галеновая форма и часть указанной формы, которую получают разделением, имеют одинаковые параметры растворения.
UAA200810556A 2008-03-21 2008-08-20 Делимая галеновая форма модифицированного высвобождения активного ингредиента UA86731C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0801561A FR2928836B1 (fr) 2008-03-21 2008-03-21 Forme galenique secable permettant une liberation modifiee du principe actif

Publications (1)

Publication Number Publication Date
UA86731C2 true UA86731C2 (ru) 2009-05-12

Family

ID=39796790

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200810556A UA86731C2 (ru) 2008-03-21 2008-08-20 Делимая галеновая форма модифицированного высвобождения активного ингредиента

Country Status (37)

Country Link
US (3) US20090238870A1 (ru)
EP (2) EP2103302A1 (ru)
JP (2) JP5231906B2 (ru)
KR (3) KR20090101048A (ru)
CN (1) CN101347414B (ru)
AP (1) AP2729A (ru)
AR (1) AR067993A1 (ru)
AU (1) AU2008207680B8 (ru)
BR (1) BRPI0803631A2 (ru)
CA (1) CA2629670C (ru)
CL (1) CL2008002486A1 (ru)
CO (1) CO6020017A1 (ru)
CR (2) CR10317A (ru)
CU (1) CU23970B1 (ru)
EA (1) EA200801862A1 (ru)
EC (1) ECSP088727A (ru)
FR (1) FR2928836B1 (ru)
GT (1) GT200800163A (ru)
HK (1) HK1127280A1 (ru)
HN (1) HN2008001466A (ru)
IL (1) IL193611A0 (ru)
JO (1) JO3052B1 (ru)
MA (1) MA31218B1 (ru)
ME (1) ME01031B (ru)
MX (1) MX2008011579A (ru)
MY (1) MY150660A (ru)
NI (1) NI200800256A (ru)
NZ (1) NZ570715A (ru)
PE (1) PE20090991A1 (ru)
SA (1) SA08290555B1 (ru)
SG (1) SG155819A1 (ru)
SV (1) SV2008003023A (ru)
TW (1) TWI396561B (ru)
UA (1) UA86731C2 (ru)
UY (1) UY31307A1 (ru)
WO (1) WO2009125087A1 (ru)
ZA (1) ZA200807354B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1940467T3 (da) 2005-09-09 2017-02-13 Paladin Labs Inc Lægemiddelsammensætning med langvarig frigivelse
US20070160960A1 (en) * 2005-10-21 2007-07-12 Laser Shot, Inc. System and method for calculating a projectile impact coordinates
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TR201103946A1 (tr) 2011-04-22 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan gliklazid formülasyonları.
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ITFI20130184A1 (it) 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
CN106892856A (zh) * 2017-02-06 2017-06-27 山东科源制药股份有限公司 一种格列齐特粗品重结晶的制备方法
EP4121013A1 (en) 2020-03-16 2023-01-25 Grünenthal GmbH Scored tablet

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353887A (en) * 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
US4851230A (en) * 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
JPH069375A (ja) * 1992-04-10 1994-01-18 Takeda Chem Ind Ltd 分割可能な連結錠剤
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
ES2216335T3 (es) * 1997-12-08 2004-10-16 Bristol-Myers Squibb Company Nuevas sales de metformina y procedimiento.
AP1224A (en) * 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
JP2006052230A (ja) * 1998-04-03 2006-02-23 Kyowa Hakko Kogyo Co Ltd 分割錠剤及びプレススルーパック
WO1999051207A1 (fr) * 1998-04-03 1999-10-14 Kyowa Hakko Kogyo Co., Ltd. Comprime secable et conditionnement au travers duquel appliquer une force de pression
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
CZ300551B6 (cs) * 1999-03-31 2009-06-17 Janssen Pharmaceutica N. V. Predželatinovaný škrob v rízene se uvolnující formulaci
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
DE10117208A1 (de) * 2001-04-06 2002-10-10 Wolff Walsrode Ag Verfahren zur Herstellung von niederviskosen, wässrigen Celluloseetherlösungen
CN1294908C (zh) * 2003-06-08 2007-01-17 安徽省医药科技实业公司 口服格列齐特缓释制剂
AU2004318976B2 (en) * 2004-04-29 2009-04-09 Lotus Pharmaceutical Co., Ltd. Oral modified-release lozenges and their preparation method
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
EP1827453A1 (en) * 2004-12-06 2007-09-05 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
DE102005014141B4 (de) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablettenförmige Retardzubereitung gegen Schwindel
US20060280790A1 (en) * 2005-04-08 2006-12-14 Ju Tzuchi R Pharmaceutical formulations
AU2006280656B2 (en) * 2005-08-18 2012-09-20 Teijin Limited Preparation with accurate dose-dividing function
JP5046501B2 (ja) * 2005-08-18 2012-10-10 帝人ファーマ株式会社 複数の薬物を分離して保持する錠剤
DK1940467T3 (da) * 2005-09-09 2017-02-13 Paladin Labs Inc Lægemiddelsammensætning med langvarig frigivelse
JOP20180109A1 (ar) * 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
WO2008018569A1 (fr) * 2006-08-10 2008-02-14 Takeda Pharmaceutical Company Limited Composition pharmaceutique
WO2008062470A2 (en) * 2006-10-19 2008-05-29 Torrent Pharmaceuticals Limited Stabilized controlled release dosage form of gliclazide
JP2008208078A (ja) * 2007-02-27 2008-09-11 Takada Seiyaku Kk 分割錠剤

Also Published As

Publication number Publication date
NI200800256A (es) 2010-02-11
JP2009227651A (ja) 2009-10-08
AR067993A1 (es) 2009-10-28
AU2008207680A1 (en) 2009-10-08
CN101347414A (zh) 2009-01-21
CU23970B1 (es) 2013-12-27
EP2103302A1 (fr) 2009-09-23
CA2629670A1 (fr) 2008-10-01
JP5231906B2 (ja) 2013-07-10
MY150660A (en) 2014-02-14
EA200801862A1 (ru) 2009-10-30
UY31307A1 (es) 2008-10-31
KR20110112266A (ko) 2011-10-12
SG155819A1 (en) 2009-10-29
JO3052B1 (ar) 2017-03-15
BRPI0803631A2 (pt) 2011-03-29
HK1127280A1 (en) 2009-09-25
US20140221449A1 (en) 2014-08-07
US20130295176A1 (en) 2013-11-07
IL193611A0 (en) 2009-08-03
MA31218B1 (fr) 2010-03-01
FR2928836A1 (fr) 2009-09-25
SV2008003023A (es) 2010-07-29
CO6020017A1 (es) 2009-03-31
FR2928836B1 (fr) 2011-08-26
US20090238870A1 (en) 2009-09-24
GT200800163A (es) 2010-05-21
CU20080179A7 (es) 2011-04-26
CL2008002486A1 (es) 2008-12-26
MX2008011579A (es) 2009-09-21
ECSP088727A (es) 2008-10-31
CN101347414B (zh) 2011-11-23
AP2729A (en) 2013-08-31
NZ570715A (en) 2010-10-29
AU2008207680B8 (en) 2010-05-13
CA2629670C (fr) 2012-04-17
JP2010209103A (ja) 2010-09-24
AP2008004614A0 (en) 2008-10-31
SA08290555B1 (ar) 2011-07-20
TW200940109A (en) 2009-10-01
CR20140334A (es) 2014-08-20
KR20150035829A (ko) 2015-04-07
ZA200807354B (en) 2008-11-26
KR20090101048A (ko) 2009-09-24
CR10317A (es) 2008-11-26
HN2008001466A (es) 2011-04-25
KR101693189B1 (ko) 2017-01-05
ME01031B (me) 2012-10-20
AU2008207680B2 (en) 2010-04-22
TWI396561B (zh) 2013-05-21
PE20090991A1 (es) 2009-07-18
WO2009125087A1 (fr) 2009-10-15
EP3025706A1 (fr) 2016-06-01

Similar Documents

Publication Publication Date Title
UA86731C2 (ru) Делимая галеновая форма модифицированного высвобождения активного ингредиента
UY33735A (es) Compuestos antivirales
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MD20150091A2 (ru) Противовирусные соединения
MX2010009646A (es) Agentes terapeuticos antivirales.
WO2011017108A3 (en) Cyclopropyl modulators of p2y12 receptor
MX2011012058A (es) Compuestos antivirales.
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
MX2010007490A (es) Preparacion de derivados de sulfamida.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
EA201101194A1 (ru) Применение розувастатин лактолов в качестве лекарственных препаратов
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
WO2009115084A3 (de) Pyrrolopyrimidin-derivate und deren verwendungen
MY156769A (en) Heat-aging-resistant polyamides
MX2010010597A (es) Procesos para la preparacion de derivados de dioxina benzofusionados.
UA107671C2 (en) N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
CO6321288A2 (es) Sales de compuestos inhibidores de vih
MX339361B (es) Derivados de alternano.
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.